# GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

Source: [PLOS Genetics](https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012373) · 2026-11-19 · Life
Page: https://themorning.science/story/gpcr-g-q-signaling-drives-adaptive-resistance-to-mek-inhibition-in-braf-mutant-m-0b7bdcc3c6d85852
Kind: research · Impact: medium

## In brief

- BRAFV600E mutations drive constitutive MAPK signaling across various cancers.
- Resistance to MEK inhibitors such as trametinib undermines their clinical benefit.
- The study reports that GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma.

## Why it matters

The study identifies a signaling pathway that can sustain MAPK activity despite MEK inhibition, which may point to ways of overcoming treatment resistance in BRAF-mutant melanoma.

## Timeline

- 2026-11-19: Study published in PLOS Genetics

## Coverage

- [GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma](https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012373) — PLOS Genetics, 2026-11-19

Tags: melanoma, braf, mek inhibition, gpcr, drug resistance

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
